Creative Biolabs

Executive Summary

Creative Biolabs is a US-based contract research organization (CRO) founded in 2005 and headquartered in Shirley, New York. The company specializes in custom antibody discovery, engineering, characterization, and production services, serving pharmaceutical, biotechnology, and academic clients globally. With over a decade of experience, Creative Biolabs has established itself as a comprehensive partner for antibody development, from early-stage drug discovery to clinical support. Its core offerings include hybridoma development, phage display, antibody sequencing, recombinant antibody production, and various assay services. The company operates in the competitive CRO market, leveraging its expertise in biologics and diagnostics to address the growing demand for antibody-based therapeutics and diagnostics. Creative Biolabs is well-positioned to benefit from the expanding biologics market, driven by increasing R&D investments in monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. The company's ability to provide customizable, high-quality services at competitive prices supports client retention and new business acquisition. However, as a private company, it faces challenges in scaling operations and competing with larger CROs. Future growth will likely hinge on expanding service capabilities, such as integrating AI-driven antibody design or offering more advanced modalities like cell and gene therapy support. With a strong foundation and a client-focused approach, Creative Biolabs is poised for steady growth in the CRO space.

Upcoming Catalysts (preview)

• Q4 2026Launch of AI-powered antibody design platform70% success
• Q2 2027Strategic partnership with a top 20 pharma for antibody discovery50% success
• Q3 2026Expansion into cell therapy CRO services60% success